Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Phase 2 Recruiting
70 enrolled
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Phase 2 Recruiting
60 enrolled
Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma
Phase 1 Recruiting
32 enrolled
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
Phase 2/3 Recruiting
193 enrolled
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Phase 2 Recruiting
100 enrolled
Studies on Tumors of the Thyroid
Recruiting
2,500 enrolled
Evaluation and Treatment of Neurosurgical Disorders
Recruiting
5,000 enrolled
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Recruiting
2,415 enrolled
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Recruiting
1,150 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Phase 2 Recruiting
48 enrolled
Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery
Phase NA Recruiting
70 enrolled
DDAVP for Pituitary Adenoma
Phase NA Recruiting
22 enrolled
Natural History Study of Parathyroid Disorders
Recruiting
3,000 enrolled
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Phase 1/2 Recruiting
56 enrolled
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
Recruiting
2,000 enrolled
Diagnosing and Treating Low Blood Sugar Levels
Recruiting
1,500 enrolled
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Phase 2 Recruiting
130 enrolled
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Recruiting
5,000 enrolled
Diagnosis of Pheochromocytoma
Phase 1 Recruiting
3,000 enrolled
Natural History Study of Children and Adults With Medullary Thyroid Cancer
Recruiting
259 enrolled
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Phase 1 Recruiting
70 enrolled
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 Recruiting
320 enrolled
Natural History of Familial Carcinoid Tumor
Recruiting
1,600 enrolled
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
Phase 1/2 Recruiting
66 enrolled
Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer
Recruiting
500 enrolled
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Phase 2 Recruiting
740 enrolled
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Phase 2 Recruiting
70 enrolled
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
Phase 1 Recruiting
120 enrolled
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Recruiting
300 enrolled